Teyi Pharmaceutical Group Co.,Ltd

002728

CNE100001WK6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-07-01 EDT			5-day change	1st Jan Change
8.43 ^CNY	+2.06%		+7.66%	-34.14%

06-12	Teyi Pharmaceutical to Buy Back Up to 120 Million Yuan Shares; Shares Up 3%	MT
06-11	Teyi Pharmaceutical Group Co.,Ltd announces an Equity Buyback for CNY 120 million worth of its shares.	CI

Teyi Pharmaceutical Group Co.,Ltd authorizes a Buyback Plan.

June 10, 2024

The Board of Directors of Teyi Pharmaceutical Group Co.,Ltd has authorized a buyback plan on June 11, 2024.

Latest news about Teyi Pharmaceutical Group Co.,Ltd

Teyi Pharmaceutical to Buy Back Up to 120 Million Yuan Shares; Shares Up 3%	06-12	MT
Teyi Pharmaceutical Group Co.,Ltd announces an Equity Buyback for CNY 120 million worth of its shares.	06-11	CI
Teyi Pharmaceutical Group Co.,Ltd authorizes a Buyback Plan.	06-10	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Teyi Pharmaceutical Group Co.,Ltd Approves the Cash Dividend for 2023	03-28	CI
Teyi Pharmaceutical Group Co.,Ltd Proposes Final Cash Dividend for the Year 2023	03-08	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Teyi Pharmaceutical Group Co.,Ltd announced that it has received CNY 274.999916 million in funding from AEGON-Industrial Fund Management Co. Ltd., Donghai Funds Management Co., Ltd., Caitong Fund Management Co., Ltd., Allianz Insurance Asset Management Co., Ltd., Nuode Asset Management Co., Ltd., China Great Wall Securities Co.,Ltd.	23-09-27	CI
Teyi Pharmaceutical's Hypertension Drug Passes Regulatory Evaluation	23-09-20	MT
Teyi Pharmaceutical Group Co.,Ltd(XSEC:002728) added to S&P Global BMI Index	23-09-18	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2022, Payable on May 26, 2023	23-05-19	CI
Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for 2022	23-05-17	CI
Teyi Pharmaceutical Group Co.,Ltd Propose Final Cash Dividend for 2022	23-04-26	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Teyi Pharmaceutical Proposes Guangzhou Branch	23-03-22	MT
Teyi Pharmaceutical Ties Up With Educational Institution for Anti-Cough Tablets Study	22-12-21	MT
China stocks end lower as COVID outbreaks cast doubts on reopening	22-11-21	RE
China stocks fall as COVID outbreaks dash hopes of eased curbs	22-11-20	RE
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Management Appointments	22-06-28	CI
Teyi Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 10, 2022	22-04-29	CI
Teyi Pharmaceutical Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI

Chart Teyi Pharmaceutical Group Co.,Ltd

Duration

Period

More charts

TEYI PHARMACEUTICAL GROUP CO., LTD, formerly Guangdong Taicheng Pharmaceutical Co., Ltd., is principally engaged in the production and sale of pharmaceuticals. The Company primarily provides Chinese traditional patent medicines, including cough arresting and phlegm removing medicine series, kidney reinforcing medicine series and anti-infection medicine series, among others. The Company's products mainly include tablets, granules, medicinal tea, syrup, decocted extracts, capsules, powder, ointment, cream, as well as oral solutions, among others.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.43

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TEYI PHARMACEUTICAL GROUP CO.,LTD	-34.14%	592M
ELI LILLY AND COMPANY	+55.55%	816B
NOVO NORDISK A/S	+40.91%	634B
JOHNSON & JOHNSON	-6.83%	351B
MERCK & CO., INC.	+17.15%	323B
ABBVIE INC.	+7.09%	293B
ASTRAZENECA PLC	+13.57%	238B
ROCHE HOLDING AG	+1.60%	222B
NOVARTIS AG	+13.51%	218B
AMGEN INC.	+7.87%	167B

Other Pharmaceuticals